Tetra Bio-Pharma Competitors and Similar CompaniesClear all
Tetra Bio-Pharma's competitors and similar companies include Cardiol Therapeutics, Cann Group and Diverse Biotech.
 Tetra Bio-Pharma Tetra Bio-Pharma is a company developing biopharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. |  Cardiol Therapeutics Cardiol Therapeutics is a company that produces pharmaceutical cannabidiol and develops cannabidiol medicines for heart disease. |  Diverse Biotech Diverse Biotech is a biopharmaceutical research company committed to discovering and developing novel therapies from its proprietary conjugate drug synthesis platform. | ||
Founding Date | Founding Date 2015 | Founding Date 2017 | Founding Date 2014 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Ottawa, CA HQ Longueuil, CA | Locations Oakville, CA HQ | Locations Bundoora, AU HQ | Locations Orlando, US HQ |
Employees | Employees 33 | Employees N/A | Employees N/A | Employees 4 |
Valuation ($) | Valuation ($) 1.7 m | Valuation ($) 98.2 m | Valuation ($) 22 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $11.3m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $8.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $5.2m (FY, 2025) | Gross profit N/A |
Net income | Net income ($52.2m) (FY, 2021) | Net income ($33.8m) (FY, 2025) | Net income ($22.3m) (FY, 2025) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Cardiol Therapeutics
HQ
Oakville, CA
Cardiol Therapeutics is a company that produces pharmaceutical cannabidiol and develops cannabidiol medicines for heart disease.
View companyDiverse Biotech
HQ
Orlando, US
Employees
4
Diverse Biotech is a biopharmaceutical research company committed to discovering and developing novel therapies from its proprietary conjugate drug synthesis platform.
View company